---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-022310"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:30:51.541207+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Anebulo Pharma Q1 net loss $2.2M; advances IV selonabant Phase 1 study

## Summary
- Net loss of $2.2M ($0.05/sh) in Q1 FY2026, flat vs prior year; operating expenses $2.3M.
- Cash $10.4M at Sept 30, 2025; plus $3M available under loan agreement.
- First subjects dosed in Phase 1 SAD study of IV selonabant for pediatric cannabis toxicity; FDA-cleared design.
- Received $994,300 second-year tranche of NIDA/NIH grant to support the SAD study.
- Board continues strategic review including proposed reverse stock split and going-private transaction; SEC comments delayed.

## SEC filing metadata
- accession: 0001493152-25-022310
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315225022310/0001493152-25-022310-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315225022310/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-022310
- JSON: https://secwatch.observer/filing/0001493152-25-022310.json
- Plain text: https://secwatch.observer/filing/0001493152-25-022310.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.